Geenius HCV Supplemental Controls - Hepatitis C virus total antibody IVD, control
Australia TGA ARTG Registered Device · Bio-Rad Laboratories Pty Ltd · Bio-Rad · Class III · Started October 28, 2020
Good Name: Bio-Rad Laboratories Pty Ltd - Geenius HCV Supplemental Controls - Hepatitis C virus total antibody IVD, control
- Risk Class
- Class III
- Product Type
- IVD
- ARTG Category
- IVD
- Start Date
- October 28, 2020
- Effective Date
- October 28, 2020
- Name
- Bio-Rad
- Country
- France
- Address
- 3 Boulevard Raymond Poincare, 92430 MARNES-LA-COQUETTE
For monitoring system performance of the Geenius HCV Supplemental Assay.
Access comprehensive regulatory information for Geenius HCV Supplemental Controls - Hepatitis C virus total antibody IVD, control in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Bio-Rad Laboratories Pty Ltd, manufactured by Bio-Rad in France. The device registration started on October 28, 2020.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.